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Melanocytes: the start and stop of it
Cellular senescence controls the lifespan of mammalian cells 
and prevents unlimited proliferation that, if unchecked, can 
lead to cancer. Telomere length was thought to control cell 
senescence. Recently, reports about a variety of tumor types, 
including melanomas, have indicated that oncogenes them-
selves can regulate proliferative mechanisms of cells. Nevi are 
benign tumors of melanocytes, which often harbor mutations 
in the protein kinase BRAF. Short-term expression of BRAFE600 
induces proliferation, suggesting that this mutation is oncoge-
nic and contributes to early steps in melanomagenesis. More 
importantly, it was recently reported that sustained expres-
sion induced cell cycle arrest, inhibited DNA replication, 
activated p16INK41, and induced accumulation of transcrip-
tionally silent DNA foci associated with senescence. These 
results strongly suggest that BRAFE600 is an activated oncogene 
that directly contributes to the long arrest of melanocytes. This 
arrest is independent of telomere shortening. Thus, BRAFE600-
induced senescence may play a protective physiological role 
in preventing the majority of nevi from becoming melanomas. 
(Nature 436:720–4, 2005)
Jun proteins implicated in psoriasis
The etiology of psoriasis, a chronic disease affecting both skin 
and joints, remains elusive. JunB, a component of the activa-
tor protein-1 transcription factor, is dramatically reduced in 
severe psoriasis lesions. In mice, epidermis-specific disruption 
of JunB and its partner c-Jun produces both physical and mole-
cular hallmarks of psoriasis. In addition, the cytokine profile 
in these mice resembles that in human patients. To examine 
the function of the immune system in psoriasis, Wagner and 
colleagues deleted JunB and c-Jun in immunodeficient mice 
(recombination-activating gene 2-deficient or tumor necrosis 
factor receptor 1-deficient). T cells played only a minor role 
in the skin phenotypes but were critical for the development 
of the arthritic lesions. Tumor necrosis factor-α signaling also 
seems to be essential for the arthritic lesions, as these triple-
mutant mice exhibited little joint inflammation. Wagner and 
colleagues have developed a putative psoriasis mouse model, 
which will aid investigations into the molecular etiology 
and the role of the immune system in this disease. (Nature 
437:369–75, 2005)
Teaching old mast cells new tricks
Both acquired and innate immune effectors can stimulate mast 
cells to undergo degranulation and release inflammatory medi-
ators. Prostaglandins (PGs), especially PGE2, enhance degra-
nulation and inhibit release of mast-cell mediators. Using a 
mouse model system, Koller and colleagues demonstrated that 
PGE induces cutaneous inflammation in a mast cell-dependent 
manner. Strikingly, PGE stimulated more enhanced vascular 
permeability and mast-cell degranulation in older mice than 
in younger mice of the same strain. As the overall cell number, 
cell size, and level of degranulation did not change with age, 
the authors propose that the mast cells may be reprogrammed 
with age to respond more efficiently to innate inflammatory 
mediators such as PGE, as opposed to responding primarily to 
acquired immunity mediators such as antigen–immunoglobu-
lin complexes. These intriguing findings offer an explanation 
for the role of mast cells in inflammatory reactions in the skin 
of elderly patients. (J Immunol 175:5701–7, 2005)
T2 is for vitiligo
Autoimmunity has been suggested to play a role in the deve-
lopment of vitiligo, an acquired hypomelanotic skin disorder. 
The association of vitiligo with other autoimmune disorders 
and the presence of cytotoxic T lymphocytes against melano-
cyte differentiation antigens in the skin and blood of vitiligo 
patients provide evidence for this notion. A missense mutation 
(1858C/T) in the lymphoid protein tyrosine phosphatase gene 
(PTPN22) was found to be associated with autoimmune dis-
eases such as type 1 diabetes, Graves’ disease, systemic lupus 
erythematosus, and rheumatoid arthritis. This phosphatase 
is critical for the negative regulation of T-lymphocyte activa-
tion, presumably by blocking signaling from cell receptor-
associated kinases. Kemp and colleagues found that the T allele 
was overrepresented in vitiligo patients, consistent with in vitro 
results demonstrating that this change reduces the binding of 
the phosphatase to its target kinases and probably disrupts the 
downregulation of T cells in vivo. These results suggest that 
unregulated T-cell activity may play an essential role in the 
development of vitiligo. (Genes Immun 6:584–7, 2005)
Keratinocyte survival requires C/EBPβ
CCAAT/enhancer-binding protein-β (C/EBPβ) has been impli-
cated in cell transformation and tumorigenesis in breast, 
colorectal, and ovarian cancers. This protein is abundantly 
expressed in epidermal keratinocytes as well. Deletion of 
C/EBPβ in mice prevents skin tumorigenesis following car-
cinogen (7,12-dimethylbenz[a]anthracene, DMBA) treatment, 
possibly because of specific alterations in keratinocytes or 
because of systemic effects on apoptosis, immune function, 
cytokine or growth factor expression, or steroid hormone lev-
els. Smart and colleagues generated keratinocyte-specific con-
ditional knockout mice in order to examine the role of C/EBPβ 
in the epidermis. This ablation was sufficient to prevent skin 
tumorigenesis following treatment with carcinogens. C/EBPβ 
is, therefore, critical for keratinocyte survival after DMBA 
treatment. This mouse model will allow assessment of the role 
of C/EBPβ at various stages of skin tumorigenesis. (Oncogene 
advance online publication, October 3 2005, doi:10.1038/
sj.onc.1209144)
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